COMP <GO>
CVKD vs APVO // PIOTROSKI F-SCORE QUALITY
Cadrenal Therapeutics Inc. (NASDAQ) VS. Aptevo Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: CVKD 2
— APVO 0
■ METRIC PARITY
LAST: $1.13 (+8.65%) • MKT CAP: $3.7M
piotroski-score
2/9
LAST: $1.36 (+0.74%) • MKT CAP: $3.6M
piotroski-score
2/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CVKD VS. APVO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CVKD | APVO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 2/9 | 2/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 51.0 | 29.1 | +21.90 | CVKD | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.7M | $3.6M | $112.3K | CVKD | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CVKD REV | APVO REV | CVKD GROSS % | APVO GROSS % | CVKD FCF | APVO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $37.7M | $73.7M | — | — | -$12.6M | -$25.6M |
| FY 2024 | $30.7M | $68.9M | — | — | -$7.4M | -$23.8M |
| FY 2023 | $21.4M | $80.9M | — | — | -$3.5M | -$11.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CVKD // BETA —
APVO // BETA —